Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
Bioprojet SCR
Chrysalis Pharma SAS
JW Pharmaceutical Corp
Novartis AG
Sensorion SA
Sosei Heptares
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles
adriforant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azasetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-7881A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JWP-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize H4 Receptor for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmory Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones
Featured News & Press Releases
Nov 20, 2019: Drug tested for sudden hearing loss
Nov 07, 2019: Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover
Oct 23, 2019: Sensorion announce collaboration announces a poster presentation of new SENS-401 preclinical data at SFN 2019 in Chicago
Sep 11, 2019: Sensorion announces three presentations at IEB 2019 in Padua
Aug 27, 2019: LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US
Jul 11, 2019: Sensorion receives FDA IND Approval for Arazasetron (SENS-401)
Jun 28, 2019: Sensorion’s PIP is EMA-approved for two indications
Mar 31, 2019: JW Pharmaceutical receives the Technology Export Award of the 20th Republic of Korea New Drug Development Awards
Feb 13, 2019: Sensorion to present new SENS-401 data at ARO 2019 MidWinter Meeting
Dec 21, 2018: Sensorion announces publication of SENS-401 data in Otology & Neurology Jourl
Nov 07, 2018: Sensorion announces presentation of SENS-401 poster at Society for Neuroscience 2018 Annual Meeting
Aug 20, 2018: Sensorion receives approval to start Phase ll trial of SENS-401
Jun 29, 2018: Sensorion Shows Protective Effect of SENS-401 in Hearing Loss Models
Jun 06, 2018: Sensorion Announces Oral Presentation at the 15th Intertiol Conference on Cochlear Implants and Other Implantable Auditory Technologies (Ci2018)
Jun 01, 2018: Sensorion to Present SENS-401 at the 2018 BIO Intertiol Convention
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bioprojet SCR, H2 2019
Pipeline by Chrysalis Pharma SAS, H2 2019
Pipeline by JW Pharmaceutical Corp, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Sensorion SA, H2 2019
Pipeline by Sosei Heptares, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019